A
2.72
0.02 (0.74%)
| Previous Close | 2.70 |
| Open | 2.75 |
| Volume | 141,205 |
| Avg. Volume (3M) | 439,045 |
| Market Cap | 53,002,464 |
| Price / Book | 2.64 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Diluted EPS (TTM) | -2.24 |
| Current Ratio (MRQ) | 10.68 |
| Operating Cash Flow (TTM) | -22.96 M |
| Levered Free Cash Flow (TTM) | -13.95 M |
| Return on Assets (TTM) | -91.05% |
| Return on Equity (TTM) | -280.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Annovis Bio, Inc. | Bearish | Bearish |
AIStockmoo Score
-1.1
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -1.13 |
|
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 14.69% |
| % Held by Institutions | 16.09% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Lokken Investment Group Llc | 31 Mar 2025 | 29,235 |
| 52 Weeks Range | ||
| Median | 10.00 (267.65%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 03 Sep 2025 | 10.00 (267.65%) | Buy | 2.28 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Sep 2025 | Announcement | Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap |
| 02 Sep 2025 | Announcement | Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference |
| 12 Aug 2025 | Announcement | Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results |
| 07 Aug 2025 | Announcement | Annovis Completes Full Patent Transfer to Crystal Buntanetap |
| 26 Jun 2025 | Announcement | Annovis to Attend the AAIC 2025 with Four Poster Presentations |
| 19 Jun 2025 | Announcement | Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |